What Pooling Data Tells Us, or Not, About Using TAVR in the Population at Low Surgical Risk for Mortality
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe, symptomatic aortic stenosis (AS). Supporting evidence has been generated as TAVR has been tested against surgical aortic valve replacement (SAVR) in randomized trials enrolling patients at high, intermediate, and low surgical risk. Understanding the nuances of these trials and their generalizability is important for the structural heart specialist in understanding where the field currently stands and who are the appropriate patients for TAVR or SAVR, as well as the remaining questions and future directions.